Industry news

• The future of Alzheimer’s disease research needs solutions that benefit trial patients

  30 November 2022 FiercePharma

  The Alzheimer’s disease (AD) drug development landscape is exciting as of late, with three leading pharma companies expected to share data from their highly anticipated Phase 3 studies at the upcoming Clinical Trials on Alzheimer’s Disease conference in late November 2022. Each of the three investigational drugs, Eisai and Biogen’s lecanemab, Roche’s gantenerumab, and Eli Lilly’s donanemab, are monoclonal antibodies that target the reduction of amyloid beta plaques in the brain, which are widely considered to be a principal driver of AD. All of the trials targeted patients with early AD and used a primary endpoint of Clinical Dementia Rating–Sum of Boxes.

• Elusive universal flu vaccine sees success in animals with mRNA tech

  29 November 2022 Helen Floersh / FierceBiotech

  Producing a successful seasonal flu vaccine requires a bit of fortune-telling. Each vaccine can target only up to four different flu viruses, of which there are many. If scientists’ predictions about the season’s predominant strains turn out to be wrong, a lot of time and money is wasted—not to mention that the public may be left unprotected from the flu, which can be dangerous even to the young and healthy.

• The Russian Federation sees an increased share of domestic applicants for drug trials

  29 November 2022 GxPnews

  The share of domestic applicants for clinical trials of drugs in Russia has increased, including within the framework of the import substitution program, Deputy Head of the Ministry of Health of Russia Sergey Glagolev said on Friday.

• NEWS FDA approves first gene therapy for Haemophilia B

  28 November 2022 Catherine Eckford / European Pharmaceutical Review

  Hemgenix, the first gene therapy for adults with Haemophilia B has been approved by the US Food and Drug Administration (FDA).

• Investments in the production of Russian substances for medicines may amount to 50 billion rubles

  28 November 2022 GxPnews

  Investments in the production of Russian substances for medicines for 10 plants (to be launched starting from 2023) may amount to 50 billion rubles, Deputy Minister of Industry and Trade Vasily Osmakov told the media. The statement was made at the interregional economics and energy industry forum in Volgograd.

• Innovation in pharma manufacturing quality systems

  24 November 2022 Dr Eduard Cayón / European Pharmaceutical Review

  Over the last 10 years, there has been an important change of focus in pharma towards biotech products and personalised therapies. These important new treatments are now emerging into manufacturing, with implications for the way that quality is monitored, managed and assured. Dr Eduard Cayón sets out some practical advice.

• Vladislav Shestakov: “The creation of a consortium for chemical raw materials production with state participation will contribute to the achievement of technological sovereignty”

  24 November 2022 GxPnews

  One of the effective tools for achieving technological sovereignty of the domestic pharmaceutical industry may be the creation of a consortium for the production of pharmaceutical, chemical and biotechnological raw materials to meet the needs of drug production. State participation is an important condition for the creation of such a structure. 

• A biotechnological substances production line has been opened at Medsyntez plant

  23 November 2022 GxPnews

  A new workshop for the production of biotechnological substances for women’s reproductive health has opened at Medsintez plant in Novouralsk, Sverdlovsk Region, according to the official website of the Plenipotentiary Representative of the President of the Russian Federation in the Ural Federal District.

• 4,000 jobs will be created at the new pharmaceutical complex in Solnechnogorsk

  23 November 2022 GxPnews

  The Moscow Architecture Department supported the architectural and urban planning solutions of the pharmaceutical production and logistics complex planned in Esipovo Industrial Park in the Solnechnogorsk municipal district. This is reported on the website of the Committee for Architecture and Urban Planning of the Moscow region.

• “Molecular sponge” for targeted drug delivery

  22 November 2022 Marchmont Innovation News

  Researchers at the Southern Federal University (SFedU) in Rostov-on-Don have developed novel nanodimensional containers for storage, target delivery and controllable dosing of drugs.